Conclusions
NASH, PBC
PBC
TQA3526 (<10 mg/day) was safe and tolerable in healthy Chinese subjects. The exposure to TQA3526 increased in a dose-dependent manner after a single dose of 1–10 mg. The safety profile and PK/PD characteristics of TQA3526 support further evaluation of its safety and efficacy in NASH or PBC patients. The efficacy of TQA3526 (0.2 mg) is currently under investigation in a phase II study.